Neville Rodie & Shaw Inc. Holds Position in Novartis AG (NYSE:NVS)

Neville Rodie & Shaw Inc. continued to hold its position in shares of Novartis AG (NYSE:NVS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,932 shares of the company’s stock at the end of the second quarter. Neville Rodie & Shaw Inc.’s holdings in Novartis AG were worth $829,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Kernodle & Katon Asset Management Group LLC raised its position in shares of Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after buying an additional 49 shares during the period. First PREMIER Bank raised its position in shares of Novartis AG by 2.4% in the first quarter. First PREMIER Bank now owns 2,242 shares of the company’s stock worth $166,000 after buying an additional 52 shares during the period. Mosaic Family Wealth LLC raised its position in shares of Novartis AG by 3.6% in the first quarter. Mosaic Family Wealth LLC now owns 2,021 shares of the company’s stock worth $150,000 after buying an additional 71 shares during the period. Essex Investment Management Co. LLC raised its position in shares of Novartis AG by 0.8% in the first quarter. Essex Investment Management Co. LLC now owns 9,409 shares of the company’s stock worth $699,000 after buying an additional 78 shares during the period. Finally, Dubuque Bank & Trust Co. raised its position in shares of Novartis AG by 3.9% in the first quarter. Dubuque Bank & Trust Co. now owns 2,526 shares of the company’s stock worth $188,000 after buying an additional 94 shares during the period. 11.16% of the stock is owned by institutional investors and hedge funds.

Novartis AG (NVS) traded down 0.50% during trading on Friday, hitting $82.76. 1,319,136 shares of the stock were exchanged. The stock has a 50 day moving average price of $83.92 and a 200-day moving average price of $79.10. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90. The firm has a market capitalization of $193.90 billion, a PE ratio of 30.22 and a beta of 0.73.

Novartis AG (NYSE:NVS) last posted its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.06. The firm had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The company’s revenue was down 1.8% on a year-over-year basis. During the same quarter last year, the company earned $1.23 earnings per share. On average, equities research analysts anticipate that Novartis AG will post $4.73 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/08/19/neville-rodie-shaw-inc-has-829000-position-in-novartis-ag-nysenvs-updated-updated.html.

A number of equities research analysts have weighed in on the company. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis AG in a research report on Thursday, June 22nd. UBS AG restated a “neutral” rating on shares of Novartis AG in a research report on Tuesday, May 30th. Vetr downgraded Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 target price for the company. in a research report on Tuesday, April 25th. Leerink Swann restated a “market perform” rating and issued a $83.00 target price on shares of Novartis AG in a research report on Thursday, June 22nd. Finally, Credit Suisse Group downgraded Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 target price for the company. in a research report on Wednesday, July 5th. Four analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $83.56.

In other news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of Novartis AG stock in a transaction that occurred on Wednesday, July 5th. The stock was bought at an average price of $15.00 per share, with a total value of $4,000,005.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.01% of the stock is currently owned by insiders.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

What are top analysts saying about Novartis AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit